Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works

The Fas Death Factor

Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979 · see citing works

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259 · see citing works

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · see citing works

CD28/B7 SYSTEM OF T CELL COSTIMULATION

Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717 · see citing works

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · see citing works

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 1,990 · see citing works

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868 · see citing works

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589 · see citing works

Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors

Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 977 · see citing works

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.

Krummel, M. F., & Allison, J. P. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2533 · Cited by 923 · see citing works

CTLA-4 ligation blocks CD28-dependent T cell activation.

Walunas, T. L., Bakker, C. Y., & Bluestone, J. A. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2541 · Cited by 801 · see citing works

A fresh look at tumor immunosurveillance and immunotherapy

Smyth, M. J., Godfrey, D. I., & Trapani, J. A. (2001) · Nature Immunology · doi:10.1038/86297 · Cited by 747 · see citing works

OX40 Promotes Bcl-xL and Bcl-2 Expression and Is Essential for Long-Term Survival of CD4 T Cells

Rogers, P., Song, J. J., Gramaglia, I., Killeen, N. P., & Croft, M. (2001) · Immunity · doi:10.1016/s1074-7613(01)00191-1 · Cited by 645 · see citing works

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.

Chen, L., McGowan, P., Ashe, S. A., Johnston, J. A., Li, Y., Hellström, I., & Hellström, K. E. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.2.523 · Cited by 462 · see citing works

Co-stimulation in T cell responses

Chambers, C. A., & Allison, J. P. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80087-8 · Cited by 415 · see citing works

Cutting Edge: 4-1BB Is a Bona Fide CD8 T Cell Survival Signal

Takahashi, C., Mittler, R. S., & Vella, A. T. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.9.5037 · Cited by 385 · see citing works

T cell co-stimulatory molecules other than CD28

Watts, T. H., & DeBenedettet, M. A. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)80046-6 · Cited by 343 · see citing works

Costimulation of T cells for tumor immunity

Chen, L., Linsley, P. S., & Hellström, K. E. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90262-j · Cited by 315 · see citing works

TRAIL/Apo-2-ligand-induced apoptosis in human T cells

Jeremias, I., Herr, I., Böhler, T., & Debatin, K. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01 · Cited by 265 · see citing works

Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death

Hurtado, J., Kim, Y. J., & Kwon, B. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2600 · Cited by 260 · see citing works

CD28 costimulation prevents cell death during primary T cell activation

Noel, P. J., Boise, L., Green, J. M., & Thompson, C. B. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.2.636 · Cited by 260 · see citing works

Gene transfer of Fas ligand induces tumor regression in vivo

Arai, H., Gordon, D., Nabel, E. G., & Nabel, G. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13862 · Cited by 247 · see citing works

Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1

Nakashima, M., Sonoda, K., & Watanabe, T. (1999) · Nature Medicine · doi:10.1038/11383 · Cited by 244 · see citing works

B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function

Tamura, H., Dong, H., Zhu, G., Sica, G., Flies, D. B., Tamada, K., & Chen, L. (2001) · Blood · doi:10.1182/blood.v97.6.1809 · Cited by 218 · see citing works

High-affinity reactions between antigen-specific T-cell receptors and peptides associated with allogeneic and syngeneic major histocompatibility complex class I proteins.

Sykulev, Y. K., Brunmark, A. B., Tsomides, T. J., Kageyama, S., Jackson, M. R., Peterson, P. A., & Eisen, H. N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11487 · Cited by 190 · see citing works

Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand.

Georgescu, L., Vakkalanka, R., Elkon, K. B., & Crow, M. K. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119806 · Cited by 174 · see citing works

Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Rivoltini, L., Barracchini, K. C., Viggiano, V., Kawakami, Y., Smith, A., Mixon, A., Restifo, N. P., Topalian, S. L., Simonis, T. B., & Rosenberg, S. A. (1995) · PubMed · Cited by 160 · see citing works

CD28 and apoptosis

Boise, L., Noel, P. J., & Thompson, C. B. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80067-0 · Cited by 139 · see citing works

Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.

Kobayashi, H., Wood, M., Song, Y., Appella, E., & Celis, E. (2000) · PubMed · Cited by 138 · see citing works

Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

Chappell, D. B., Zaks, T. Z., Rosenberg, S. A., & Restifo, N. P. (1999) · PubMed · Cited by 133 · see citing works

The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors

Finger, L. R., Pu, J. J., Wasserman, R., Vibhakar, R., Louie, E., Hardy, R. R., Burrows, P. D., & Billips, L. G. (1997) · Gene · doi:10.1016/s0378-1119(97)00260-6 · Cited by 113 · see citing works

Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease

Tamada, K., Tamura, H., Flies, D. B., Fu, Y., Celis, E., Pease, L. R., Blazar, B. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213604 · Cited by 91 · see citing works

Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications

Strand, S., & Galle, P. R. (1998) · Molecular Medicine Today · doi:10.1016/s1357-4310(97)01191-x · Cited by 78 · see citing works

Fas counter-attack–the best form of tumor defense?

O’Connell, J., Bennett, M. W., O'Sullivan, G., Collins, J. K., & Shanahan, F. (1999) · Nature Medicine · doi:10.1038/6477 · Cited by 71 · see citing works

Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.

Lu, J., & Celis, E. (2000) · PubMed · Cited by 67 · see citing works

Functional expression of TRAIL by lymphoid and myeloid tumour cells

Zhao, S., Asgari, Z., Wang, Y., Goodwin, R. G., Andreeff, M., & Younes, A. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01630.x · Cited by 41 · see citing works

Immunoglobulin Fusion Proteins as a Tool for Evaluation of T-Cell Costimulatory Molecules

Chapoval, A. I., Zhu, G., & Chen, L. (2002) · Molecular Biotechnology · doi:10.1385/mb:21:3:259 · Cited by 12 · see citing works

Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.

van Geel (2001) · Open Repository and Bibliography (University of Luxembourg) · doi:10.1002/1531-8249(20010201)49:2 · Cited by 7 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · see citing works

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · see citing works

The biology and management of non-small cell lung cancer

Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891 · see citing works

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · see citing works

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154 · see citing works

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331 · see citing works

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · see citing works

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813 · see citing works

Immune Checkpoint Blockade in Cancer Therapy

Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,736 · see citing works

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · see citing works

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,382 · see citing works

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · see citing works

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324 · see citing works

The B7 family revisited

Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · see citing works

PD-L1 expression as a predictive biomarker in cancer immunotherapy

Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291 · see citing works

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

Duma, N., Santana-Dávila, R., & Molina, J. R. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.013 · Cited by 2,218 · see citing works

Regulation and Function of the PD-L1 Checkpoint

Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,187 · see citing works

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · see citing works

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · see citing works

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

Deng, L., Liang, H. L., Burnette, B., Beckett, M., Darga, T. E., Weichselbaum, R. R., & Fu, Y. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,101 · see citing works

Natural Innate and Adaptive Immunity to Cancer

Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,095 · see citing works

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · see citing works

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072 · see citing works

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057 · see citing works

CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer

McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,973 · see citing works

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942 · see citing works

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766 · see citing works

Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses

Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,733 · see citing works

Immunosuppressive Strategies that are Mediated by Tumor Cells

Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,699 · see citing works

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · see citing works

Inhibitory B7-family molecules in the tumour microenvironment

Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608 · see citing works

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487 · see citing works

Immune surveillance of tumors

Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,469 · see citing works

Galectins as modulators of tumour progression

Liu, F., & Rabinovich, G. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1527 · Cited by 1,435 · see citing works

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

Chen, L., & Han, X. N. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,433 · see citing works

PD-L1 Expression in Triple-Negative Breast Cancer

Mittendorf, E. A., Philips, A. V., Meric‐Bernstam, F., Qiao, N., Wu, Y., Harrington, S. M., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akçakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,394 · see citing works

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,394 · see citing works

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 ⁺ T lymphocytes are prognostic factors of human ovarian cancer

Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · see citing works

Cancer immunotherapy: harnessing the immune system to battle cancer

Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,366 · see citing works

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

Pitt, J. M., Marabelle, A., Eggermont, A. M. M., Soria, J., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,344 · see citing works

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,342 · see citing works

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,341 · see citing works

Tumor Microenvironment

Arneth, B. M. (2019) · Medicina · doi:10.3390/medicina56010015 · Cited by 1,339 · see citing works

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,324 · see citing works

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

Dovedi, S. J., Adlard, A. L., Lipowska‐Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,316 · see citing works

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · see citing works

PD-1 and PD-1 ligands: from discovery to clinical application

Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310 · see citing works

Combination cancer immunotherapy and new immunomodulatory targets

Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294 · see citing works

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Gong, J., Chehrazi‐Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,279 · see citing works

Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

Chen, L. (2004) · Nature reviews. Immunology · doi:10.1038/nri1349 · Cited by 1,257 · see citing works

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236 · see citing works

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211 · see citing works

Immune checkpoint therapy—current perspectives and future directions

Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206 · see citing works

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,180 · see citing works

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147 · see citing works

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Li, C., Lim, S., Xia, W., Lee, H., Chan, L.-C., Kuo, C., Khoo, K., Chang, S.-S., Cha, J., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,100 · see citing works

Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

Rosenwald, A., Wright, G. W., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haïoun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,095 · see citing works

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074 · see citing works

Natural selection of tumor variants in the generation of “tumor escape” phenotypes

Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058 · see citing works

Mechanisms Controlling PD-L1 Expression in Cancer

Cha, J., Chan, L.-C., Li, C., Hsu, J. L., & Hung, M. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.030 · Cited by 1,054 · see citing works

Clinical implications of T cell exhaustion for cancer immunotherapy

Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044 · see citing works

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,040 · see citing works

Lung cancer: Biology and treatment options

Lemjabbar‐Alaoui, H., Hassan, O. U., Yang, Y., & Buchanan, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,024 · see citing works

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018 · see citing works

Targeting tumor-associated macrophages to synergize tumor immunotherapy

Xiang, X., Wang, J., Lu, D., & Xu, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00484-9 · Cited by 982 · see citing works

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981 · see citing works

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

Conforti, F., Pala, L., Bagnardi, V., De Pas, T., Martinetti, M., Viale, G., Gelber, R. D., & Goldhirsch, A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30261-4 · Cited by 973 · see citing works

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y., Byers, L. A., Zhang, X., Yi, X., Dwyer, D. W., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 972 · see citing works

Expression of Programmed Death 1 Ligands by Murine T Cells and APC

Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 950 · see citing works

Cancer nanomedicine for combination cancer immunotherapy

Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 946 · see citing works

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 915 · see citing works

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

Kuang, D., Zhao, Q., Peng, C., Xu, J., Zhang, J., Wu, C. Y., & Zheng, L. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 897 · see citing works

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

Kumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y.-T., Togashi, Y., Kamada, T., Irie, T., Okumura, G., Kono, H., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.001 · Cited by 892 · see citing works

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890 · see citing works

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889 · see citing works

PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection

Petrovas, C., Casazza, J. P., Brenchley, J. M., Price, D. A., Gostick, E., Adams, W. C., Precopio, M. L., Schacker, T., Roederer, M., Douek, D. C., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061496 · Cited by 889 · see citing works

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

Wang, J., Sanmamed, M. F., Datar, I. J., Su, T. T., Ji, L., Sun, J., Chen, L., Chen, Y., Zhu, G., Yin, W., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.010 · Cited by 879 · see citing works

Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up

Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869 · see citing works

Regulatory mechanisms of PD-1/PD-L1 in cancers

Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 850 · see citing works

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

Juneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N. B., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160801 · Cited by 848 · see citing works

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

Chen, B. J., Chapuy, B., Ouyang, J., Sun, H. H., Roemer, M. G. M., Xu, M. L., Yu, H., Fletcher, C. D. �., Freeman, G. J., Shipp, M. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0855 · Cited by 839 · see citing works

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

McLaughlin, J. F., Han, G., Schalper, K. A., Carvajal‐Hausdorf, D., Pelekanou, V., Rehman, J., Velcheti, V., Herbst, R. S., LoRusso, P. M., & Rimm, D. L. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3638 · Cited by 835 · see citing works

The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice

Ansari, M. J., Salama, A. D., Chitnis, T., Smith, R. N., Yagita∥, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 806 · see citing works

Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796 · see citing works

The changing therapeutic landscape of head and neck cancer

Cramer, J. D., Burtness, B. A., Le, Q., & Ferris, R. L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0227-z · Cited by 794 · see citing works

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Kochin, V., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 794 · see citing works

Deubiquitination and Stabilization of PD-L1 by CSN5

Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793 · see citing works

PD-L1 expression in human cancers and its association with clinical outcomes

Yu, J., Wang, X., Teng, F., & Kong, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105862 · Cited by 787 · see citing works

B7-H1 pathway and its role in the evasion of tumor immunity

Dong, H., & Chen, L. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0430-2 · Cited by 276 · see citing works

In Brief

(2002) · Nature reviews. Immunology · doi:10.1038/nri882

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

Azuma, T., Yao, S., Zhu, G., Flies, A. S., Flies, S. J., & Chen, L. (2008) · Blood · doi:10.1182/blood-2007-11-123141 · Cited by 528 · see citing works

Protect the killer: CTLs need defenses against the tumor

Freeman, G. J., Sharpe, A. H., & Kuchroo, V. K. (2002) · Nature Medicine · doi:10.1038/nm0802-787 · Cited by 40 · see citing works

Effects of lung cancer cell-associated B7-H1 on T-cell proliferation in vitro and in vivo

Chen, K., Huang, H.-H., Hang, W.-H., Pan, L., & Ma, H. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165263 · Cited by 9 · see citing works